Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

(2016) Serena Nik-Zainal et al.   NATURE

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

(2016) Peter M. Anderson et al.   PEDIATRIC BLOOD & CANCER

Mutational signatures of ionizing radiation in second malignancies

(2016) Sam Behjati et al.   Nature Communications

Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-β as Involved in the Pathogenesis of Osteosarcoma

(2015) Rui Yang et al.   CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

Cancer genomics: why rare is valuable

(2015) Farzad Jamshidi et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

(2015) Michal Kovac et al.   Nature Communications

Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells

(2015) Junyun Wang et al.   Oncotarget

A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance

(2014) Alberto S. Pappo et al.   CANCER

The Architecture and Evolution of Cancer Neochromosomes

(2014) Dale W. Garsed et al.   CANCER CELL

Recurrent PTPRB and PLCG1 mutations in angiosarcoma

(2014) Sam Behjati et al.   NATURE GENETICS

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

(2014) Lars M. Wagner et al.   PEDIATRIC BLOOD & CANCER

Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma

(2014) Yu Cao et al.   PLoS One

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

(2014) Jennifer A. Perry et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

(2014) Xiang Chen et al.   Cell Reports

Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy

(2014) M. Fernanda Amary et al.   Cancer Medicine

IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma

(2013) Marieke L Kuijjer et al.   BMC CANCER

Osteosarcoma treatment – Where do we stand? A state of the art review

(2013) Anja Luetke et al.   CANCER TREATMENT REVIEWS

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone

(2013) Sam Behjati et al.   NATURE GENETICS

Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma

(2013) Patrick S Tarpey et al.   NATURE GENETICS

Mutational Processes Molding the Genomes of 21 Breast Cancers

(2012) Serena Nik-Zainal et al.   CELL

Allele-specific copy number analysis of tumors

(2010) P. Van Loo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines

(2009) Z. Duan et al.   MOLECULAR CANCER THERAPEUTICS

Development of IGF-IR inhibitors in pediatric sarcomas

(2009) E. Anders Kolb et al.   Current Oncology Reports

Insulin, insulin-like growth factors and neoplasia

(2008) Michael Pollak   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM